Slingshot members are tracking this event:

Initiation of two Phase 3 trials for Fitusiran (ALN-AT3), in treating severe hemophilia A and B patients with and without inhibitors is expected in early 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
ALNY Community voting in process

Additional Information

Additional Relevant Details  Positive Phase 1 Study Results for Once-Monthly, Subcutaneous Fitusiran (ALN-AT3) in Patients with Hemophilia A and B
Additional Relevant Details Update on 11.14.2016: Upon the initiation of the first global Phase 3 clinical trial for fitusiran, Alnylam will earn a milestone payment of $25 million
Additional Relevant Details It was first expected to initiate in mid/ late 2016.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 07, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Trials, Fitusiran, Aln-at3, Severe Hemophilia A, Hemophilia B